Sort
25,944 grants matching “neurodegeneration”
Pro-inflammatory cytokine lowering anti-inflammatory drugs
$1,728,312Nigel H. Greig · National Institute On Aging · ZIA · FY2018 · AG
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets
$1,722,003Aaron D. Gitler · Stanford University · U54 · FY2021 · NS
Alzheimer's Disease Core Center
$1,720,585Marek-Marsel M Mesulam · Northwestern University At Chicago · P30 · FY2016 · AG
Vascular mechanisms of inhibition of sEH as a novel therapy for AD/ADRD
$1,720,413Richard J Roman · University Of Mississippi Med Ctr · RF1 · FY2022 · AG
Michigan Alzheimer's Disease Core Center
$1,719,170Henry L Paulson · University Of Michigan At Ann Arbor · P30 · FY2016 · AG
Michigan Alzheimer's Disease Core Center
$1,718,713Henry L Paulson · University Of Michigan At Ann Arbor · P30 · FY2019 · AG
Alzheimers Disease Research Center - Univ. of CA Irvine
$1,718,494University Of California Irvine · P50 · FY2005 · AG
National Center for Drug Discovery in Neurodegeneration
$1,717,779Brigham And Women'S Hospital · U24 · FY2005 · NS
Organization and Dynamics of Endomembrane Pathways and Organelles
$1,717,646Jennifer Lippincott-Schwartz · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2009 · HD
Optogenetics and Transgenic Technology Core
$1,717,126Brandon Harvey · National Institute On Drug Abuse · ZIC · FY2012 · DA
Using a Health Disparity Research Framework to examine mechanisms linking Obstructive Sleep Apnea with higher Alzheimerâs disease risk in older Blacks/African-Americans
$1,716,849Omonigho A Michael Bubu · New York University School Of Medicine · R01 · FY2024 · AG
The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal Dementia
$1,715,367Hemali Phatnani · Columbia University Health Sciences · R01 · FY2025 · NS
Clarifying the association of depressive symptoms with cortico-limbic tau, cerebral blood flow, neurodegeneration, and longitudinal cognitive decline in individuals with mild cognitive impairment
$1,711,908Robert Scott Mackin · University Of California, San Francisco · R01 · FY2025 · AG
Michigan Alzheimer's Disease Core Center
$1,709,226Henry L Paulson · University Of Michigan At Ann Arbor · P30 · FY2018 · AG
Synergistic Enhancement of ER proteostasis, trafficking, and lysosomes as treatments for Dementia with Lewy bodies and Parkinsonâs disease-dementia
$1,707,089Joseph R Mazzulli · Northwestern University At Chicago · R61 · FY2024 · NS
Biomarkers of Catecholaminergic Neurodegeneration
$1,706,465David Goldstein · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS
Identification and Development of Tau-Lowering Small-Molecule Drugs
$1,703,867Lennart Mucke · J. David Gladstone Institutes · R56 · FY2019 · AG
Genetic analysis of UBQLN2-associated neurodegeneration in frontotemporal dementia
$1,700,040Randal Scot Tibbetts · University Of Wisconsin-Madison · RF1 · FY2020 · AG
Michigan Alzheimer's Disease Core Center
$1,700,024Henry L Paulson · University Of Michigan At Ann Arbor · P30 · FY2017 · AG
The Emory Alzheimer's Disease Center
$1,698,741Allan I Levey · Emory University · P50 · FY2009 · AG
p53, Aging, and Cancer
$1,696,670Curtis Harris · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Basic and Translational Studies of Inborn Errors of Metabolism
$1,696,325Forbes Porter · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2020 · HD
Down Syndrome: a potential treatment XISTs
$1,693,316Volney L Sheen · Beth Israel Deaconess Medical Center · R01 · FY2022 · HD
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
$1,692,440James Cardelli · Oleolive, Inc. · R42 · FY2022 · AG
Repurposing FDA-approved agonists of HCAR2 as novel therapeutics for Alzheimer's Disease
$1,691,548Gary E. Landreth · Indiana University Indianapolis · RF1 · FY2022 · AG